LONDON, Feb. 12, 2021 (GLOBE NEWSWIRE) — Autolus plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical firm growing next-generation programmed T cell therapies, right now introduced the closing of its beforehand introduced underwritten public providing in the US of 16,428,572 American Depositary Shares (“ADSs”) representing 16,428,572 bizarre shares, together with the train in full by the underwriters of their choice to buy an extra 2,142,857 ADSs, at a public providing worth of $7.00 per ADS. The gross proceeds to Autolus from the providing, earlier than underwriting reductions and commissions and different providing bills payable by Autolus, have been roughly $115.0 million.
J.P. Morgan and Wells Fargo Securities acted as joint bookrunners for the providing. Kempen & Co, Mizuho Securities and Needham & Firm acted as co-managers.
The securities described above have been supplied by Autolus pursuant to an efficient shelf registration assertion that was beforehand filed with the Securities and Change Fee (“SEC”). A remaining prospectus complement to the accompanying prospectus describing the phrases of the providing was filed with the SEC. Copies of the ultimate prospectus complement and the accompanying prospectus regarding the providing could also be obtained totally free from both of the joint book-running managers for the providing, J.P. Morgan Securities LLC, c/o Broadridge Monetary Options, 1155 Lengthy Island Avenue, Edgewood, NY 11717, or by phone at +1 866 803 9204 or by electronic mail at firstname.lastname@example.org; or Wells Fargo Securities, LLC, Consideration: Fairness Syndicate Division, 500 West thirty third Avenue, New York, New York, 10001, at (800) 326-5897 or electronic mail a request to email@example.com. For the avoidance of doubt, such prospectus won’t represent a “prospectus” for the needs of the Regulation (EU) 2017/1129 and has not been reviewed by any competent authority in any member state within the European Financial Space or the UK.
This press launch doesn’t represent a proposal to promote or the solicitation of a proposal to purchase securities, and shall not represent a proposal, solicitation or sale in any jurisdiction during which such supply, solicitation or sale can be illegal previous to registration or qualification beneath the securities legal guidelines of that jurisdiction.
Autolus is a clinical-stage biopharmaceutical firm growing next-generation, programmed T cell therapies for the remedy of most cancers. Utilizing a broad suite of proprietary and modular T cell programming applied sciences, the corporate is engineering exactly focused, managed and extremely lively T cell therapies which are designed to higher acknowledge most cancers cells, break down their protection mechanisms and eradicate these cells. Autolus has a pipeline of product candidates in improvement for the remedy of hematological malignancies and stable tumors.
Lucinda Crabtree, Ph.D.
Vice President, Investor Relations and Company Communications
+44 (0)7587 372 619
+44 (0)7818 430877
Susan A Noonan
S.A. Noonan Communications, LLC
+1 212 966 3650